摘要
目的:探讨免疫抑制性糖蛋白(Glycodelin)在子宫内膜癌及子宫颈癌的表达。方法:采用免疫组织化学S-P法检测Glycodelin在30例子宫内膜癌及20例子宫颈癌组织中的表达,并评价其与临床病理分期和组织学分级的关系。结果:Glycodelin在子宫内膜癌、子宫颈鳞癌和子宫颈腺癌的表达率分别为73%(22/30)、53 33%(8/15)和60%(3/5),3组之间无统计学差异(P>0 05)。各临床病理分期的阳性率(子宫内膜癌:I期75%,II期75 00%,III期50%;子宫颈癌:Ia60%,Ib44 44%,IIa66 66%)无统计学差异(P>0 05)。各组织学分级的阳性率(子宫内膜癌:G170%,G277 78%和G366 67%;子宫颈癌:G159 14%,G250 00%和G360 00%)无统计学差异,P>0 05。结论:Glycodelin在子宫内膜腺癌和子宫颈癌均有表达,其表达与临床病理分期和组织学分级无明显关系。
Aim: To study the expression of immunosuppressive glycoprotein Glycodelin in endometrial carcinoma and cervical cancer. Methods: Immunohistochemical S-P assay was used to detect the expression of Glycodelin in paraffin-embedded sections of 30 cases of endometrial carcinoma and 20 cases of cervical cancer. The relationship between Glycodelin expression and clinicopathological characteristics was evaluated. Results: The positive immunostaining rate of Glycodelin in endometrial carcinoma, squamous cell carcinoma of the cervix and adenocarcinoma of the cervix was 73%(22/30), 53.33%(8/15) and 60%(3/5), respectively; there were no significant difference between each group, P>0.05. There were no significant differences between each clinicopathological stage(in endometrial carcinoma: stage I 75.00%, stage II 75.00% and stage III 50%;in cervical cancer:stage Ia 60%,stage Ib 44.44% and stage IIa 66.66%),P>0.05. No significant differences between each histological grade were found (in endometrial carcinoma: G_1 70%, G_2 77.78% and G_3 66.67%;in cervical cancer:G_1 59.14%,G_2 50.00% and G_3 60.00%),P>0.05. Conclusion:Glycodelin is expressed in endometrial carcinoma and cervical cancer,its expression is not correlated with clinicopathological staging or histological grade.
出处
《暨南大学学报(自然科学与医学版)》
CAS
CSCD
2004年第2期185-189,共5页
Journal of Jinan University(Natural Science & Medicine Edition)
基金
广东省医学科研课题项目(A2003387)